Literature DB >> 15204700

Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog.

M Strolin Benedetti1, R Coupez, R Whomsley, J M Nicolas, P Collart, E Baltes.   

Abstract

1: The pharmacokinetics and metabolism of 14C-levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog after a single oral dose were investigated. Moreover, the in vitro hydrolysis of levetiracetam to its major carboxylic metabolite by rat tissue homogenates was investigated to identify tissues involved in the production of the metabolite. Data are also presented on the induction of the enzyme(s) involved in levetiracetam hydrolysis in the rat. 2: Levetiracetam was rapidly and almost completely absorbed. The unchanged drug accounted for a very high percentage of plasma radioactivity. Levetiracetam did not bind to plasma proteins. Although brain radioactivity concentrations were lower than those of whole blood at early time points, brain-to-blood ratios increased over time. The predominant route of elimination of total 14C was excretion via urine, accounting for about 81, 93, 87 and 89% of the dose in the mouse, rat, rabbit and dog, respectively. Consequently, levetiracetam was poorly metabolized. It was submitted in vivo to hydrolysis and/or oxidation. Hydrolysis of the amide function of levetiracetam produced the corresponding acid. However, levetiracetam could also be oxidized at positions 3 and 4 of the 2-oxopyrrolidine ring. Finally, the compound and the corresponding acid metabolite could be oxidized at position 5 of the 2-oxopyrrolidine ring and then hydrolysed with the opening of the ring. 3: All the investigated rat tissues (liver, kidney, lung, brain, small intestine mucosa) had the potential to produce the acid metabolite. By contrast, the acid was undetectable following incubation of levetiracetam with buffer alone or heat-denaturated liver fractions. 4: No marked species or sex differences were observed in the absorption, disposition and metabolism of levetiracetam. 5:The hydrolysis of levetiracetam is carried out by an enzymatic process characterized by a broad tissue distribution. In the rat, the enzyme system hydrolysing levetiracetam is not induced by phenobarbital, at least under the experimental conditions used herein, whereas the enzyme system(s) involved in the other metabolic pathways is induced. Copyright 2004 Taylor and Francis Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15204700     DOI: 10.1080/0049825042000196749

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  10 in total

1.  The pharmacokinetics of commonly used antiepileptic drugs in immature CD1 mice.

Authors:  Geoffrey J Markowitz; Shilpa D Kadam; Dawn M Boothe; Natasha D Irving; Anne M Comi
Journal:  Neuroreport       Date:  2010-04-21       Impact factor: 1.837

2.  Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice.

Authors:  Eric W Fish; Abigail E Agoglia; Michael C Krouse; R Grant Muller; J Elliott Robinson; C J Malanga
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

3.  Disposition of Extended Release Levetiracetam in Normal Healthy Dogs After Single Oral Dosing.

Authors:  M J Beasley; D M Boothe
Journal:  J Vet Intern Med       Date:  2015-08-20       Impact factor: 3.333

4.  Levetiracetam rectal administration in healthy dogs.

Authors:  R K Peters; T Schubert; R Clemmons; T Vickroy
Journal:  J Vet Intern Med       Date:  2014-01-13       Impact factor: 3.333

5.  Effect of chronic administration of phenobarbital, or bromide, on pharmacokinetics of levetiracetam in dogs with epilepsy.

Authors:  K R Muñana; J A Nettifee-Osborne; M G Papich
Journal:  J Vet Intern Med       Date:  2015-02-25       Impact factor: 3.333

6.  Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus.

Authors:  Giulia Cagnotti; Rosangela Odore; Giulia Gardini; Stefano Amedeo; Iride Bertone; Giulia Guerriero; Laura Lentini; Elena Dappiano; Antonio D'Angelo
Journal:  BMC Vet Res       Date:  2018-06-18       Impact factor: 2.741

Review 7.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

8.  Neuroinflammation in epileptogenesis: Insights and translational perspectives from new models of epilepsy.

Authors:  Melissa L Barker-Haliski; Wolfgang Löscher; H Steve White; Aristea S Galanopoulou
Journal:  Epilepsia       Date:  2017-07       Impact factor: 6.740

Review 9.  The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism.

Authors:  Hueng-Chuen Fan; Herng-Shen Lee; Kai-Ping Chang; Yi-Yen Lee; Hsin-Chuan Lai; Pi-Lien Hung; Hsiu-Fen Lee; Ching-Shiang Chi
Journal:  Int J Mol Sci       Date:  2016-08-01       Impact factor: 5.923

10.  Effects of Antiepileptic Drugs on Spontaneous Recurrent Seizures in a Novel Model of Extended Hippocampal Kindling in Mice.

Authors:  Hongmei Song; Uilki Tufa; Jonathan Chow; Nila Sivanenthiran; Chloe Cheng; Stellar Lim; Chiping Wu; Jiachun Feng; James H Eubanks; Liang Zhang
Journal:  Front Pharmacol       Date:  2018-05-18       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.